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Epilepsy is a relatively common neurological
condition affecting 0.5-1% of the worldís popula-
tion. The classical antiepileptic drugs comprise
phenytoin, phenobarbital, carbamazepine, ethosux-
imide, valproic acid and various benzodiazepines
still widely utilized in the treatment of the various
forms of epilepsy. In recent years several new
drugs have been employed, e.g. felbamate, fos-
phenytoin, gabapentin, lamotrigine, tiagabine, top-
iramate, vigabatrin and zonisamide. However,
about 25% of patients are resistant to the available
medical therapies. All the currently approved
antiepileptic drugs have dose-related toxicity and
idiosyncratic side effects (1). Antiepileptic drugs
belong to many different classes of chemical com-
pounds and act via various mechanisms (2). This
makes it difficult to identify a common pharma-
cophore. 
Among the compounds tested for anticonvul-
sant activity are phthalimide derivatives (3-5).
Based on the structure-activity relationships for
4-aminobenzamide derivatives (especially
ameltolide) and thalidomide, Vamecq et al. stud-
ied N-phenyl phthalimide derivatives as rigidified
analogues of ameltolide and designed the 4-
amino-N-(2,6-dimethylphenyl)phthalimide model
and subsequent phthalimide pharmacophore with-
out the 4-amino group in the phthaloyl moiety
(Fig. 1) (5). Similarly to ameltolide, N-phenylph-
thalimide derivatives exhibit a phenytoin-like
profile i.e. they are quite potent in the maximal
electroshock seizure (MES) test and are inactive
in the subcutaneous pentylenetetrazole (ScMet)
test.
Marona and KieÊ-Kononowicz found some
anticonvulsant compounds among the 2-N-(phthal-
imido)-1-alkyl esters of aromatic and heterocyclic
acids (4). The highest activity was shown by isomer
R of 2-N-(phthalimido)-1-butyl-(4-benzyloxy)ben-
zoate (Fig. 2).
This study indicated that a rigid phenyl ring
substituted at the phthalimide nitrogen atom is not
an essential element for anticonvulsant activity. In
our research we synthesized two series of phthalim-
ides: those possessing an N-phenoxyalkyl moiety
substituted at position 3 or 4 of the phenyl ring and
a series of N-alkenyl or alkinyl phthalimides. We
evaluated their anticonvulsant activity and estimated
their lipophilicity in silico using computer pro-
grams. The target compounds were synthesized
using two methods: by conventional alkylation of
phthalimide with appropriate bromides under phase-
transfer conditions (compounds 1-9, 11, Scheme 1)
(6) and, by using the Mitsunobu reaction, from
appropriate alcohols and phthalimide in the presence
of diethyl azodicarboxylate (DEAD) and triph-
enylphosphine (compounds 10, 12-18, Scheme 3)
(7). Phenoxyalkyl bromides were prepared from the
corresponding phenols using the standard procedure
(Scheme 2). 
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Compounds 1-3, 7, 8, 12-15 and 18 were
unknown in the literature to date, but the other
compounds (4-6, 9-11 and 16-17) were described
as intermediate products in the synthesis of amines,
used in the preparation of the final compounds.
Compounds 4-6, 9, 11, 16 and 17 were obtained by
the reaction of appropriate bromides (comp. 4-6, 9,
11) or chlorides (16, 17) and potassium phthalim-
ide in anhydrous THF. Compound 10 was obtained
by the reaction of 4-pentynol with phthalimide
under Mitsunobu reaction conditions.
Physicochemical data for all the compounds is
given in Table 3.
The anticonvulsant properties of the com-
pounds obtained were evaluated by the
Antiepileptic Drug Development Program,
Epilepsy Branch, National Institute of
Neurological and Communicative Disorders and
Stroke, National Institute of Health in Bethesda,
USA. Phase I of these screenings included two
major convulsant tests: maximal electroshock
(MES) and subcutaneous pentylenetetrazole
(ScMet), as well as a toxicity screen (Tox). The
MES test is a model for generalized tonic-clonic
(grand-mal) seizures, whereas the ScMet test is a
model which primarily identifies compounds that
raise the seizure threshold. The neurological toxic-
ity was evaluated in mice using the rotorod test.




All the melting points were measured in glass
capillary tubes using Mel-Temp Laboratory Devices
Inc. USA apparatus, and are uncorrected. TLC analy-
sis was conducted on Al sheets with a 0.2 mm layer
of silica gel (60F254 Merck). 1H NMR spectra were
recorded on a Varian Mercury-VX instrument at 300
MHz using TMS as an internal standard in DMSO-d6
(for comp. 1-9) or CDCl3 (for comp. 10-18).
Elemental analyses were performed on an Elemental
Vario-EL III apparatus. Reagents: phthalimide,
potassium phthalimide, TEBA, triphenylphosphine,
DEAD, 1,2-dibromoethane, 1,3-dibromopropane
and solvents were commercial reagents (Aldrich,
Fluka). The theoretical values of logP were calculat-
ed using the Pallas (logPPALLAS) and clogP programs. 
Figure 1. Anticonvulsant compounds designed from ameltolide and thalidomide
Figure 2. The most active compound among the 2-N-(phthalimi-
do)-1-alkyl esters of aromatic and heterocyclic acids (4)
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Scheme 1. Synthesis of N-substituted phthalimides from bromides
Scheme 2. Synthesis of phenoxyalkyl bromides
Scheme 3. Synthesis of N-substituted phthalimides by the Mitsunobu reaction
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Chemistry
General synthetic procedure for the prepara-
tion of N-substituted phthalimides from bromides
(1-9, 11)
A mixture of potassium phthalimide (10
mmol), K2CO3 (30 mmol), and benzyltriethylammo-
nium chloride (TEBA) (1 mmol) in 50 mL of ace-
tone was refluxed for 40 min. An appropriate bro-
mide (10 mmol) in 10 mL of acetone was added
dropwise and refluxed for additional 6 h. The pre-
cipitate was filtered and the solvent was evaporated
under reduced pressure. The residue was washed
twice with 2% NaOH solution and water and puri-
fied by column chromatography (eluent: CH2Cl2) to
afford pure N-substituted phthalimide. Compounds
1-6, 8 and 9 were also crystallized from ethanol. 
General synthetic procedure for the preparation
of bromides 
Bromides for the synthesis of compounds 1-9
were obtained from appropriate phenols and an
excess of 1,2-dibromoethane (1-6) or 1,3-dibromo-
propane (7-9) by heating for 6 h (3 h at 60OC, 3 h
reflux) in sodium n-propanolate. Unpurified raw
materials were used for further synthesis. The bro-
mide for the synthesis of 11 was commercially avail-
able.
General procedure for the preparation of N-sub-
stituted phthalimides from alcohols (10, 12-18)
A mixture of phthalimide (15 mmol), triph-
enylphosphine (15 mmol), and an appropriate alcohol
(15 mmol) in 10 mL of dry THF was cooled to 0OC.
Diethyl azodicarboxylate (DEAD) (15 mmol) in 10
ml of dry THF was slowly added dropwise (30 min);
the reaction mixture was then allowed to warm to
room temperature and stirred overnight. The solvent
was evaporated under reduced pressure and the
residue suspended in Et2O. The precipitate was fil-
tered, the solvent was evaporated and the residue was
purified by column chromatography (eluent:
CH2Cl2) to afford pure N-substituted phthalimide. 
Table 1. Anticonvulsant and neurotoxicity screening data for phenoxyalkyl phthalimides (1-9)
Compd. Dose Activity
no. [mg/kg] MESa ScMetb Toxc
0.5h 4h 0.5 4 0.5 4
30 0/1 0/1 0/1 0/1 0/4 0/2
1 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 2/5 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
2 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
3 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
4 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
5 100 0/3 0/3 0/1 0/1 1/8 0/4
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
6 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
7 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
8 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
9 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
a Number of animals protected/number of animals tested in the MES test.
b Number of animals protected/number of animals tested in the ScMet test.
c Number of animals exhibiting toxicity/number of animals tested in the rotorod test.
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Pharmacology
The anticonvulsant properties of the com-
pounds obtained were evaluated by the
Antiepileptic Drug Development Program,
Epilepsy Branch, National Institute of Neurological
and Communicative Disorders and Stroke, National
Institute of Health in Bethesda, USA. Preliminary
screenings in this program included two major con-
vulsant tests: maximal electroshock (MES) and
subcutaneous pentylenetetrazole (ScMet), as well
as a toxicity screen (Tox). Compounds were inject-
ed intraperitoneally into mice as suspensions in
0.5% methylcellulose at three dosage levels (30,
100 and 300 mg/kg) 30 min or 4 h before evaluation
of their activity in these tests. The MES were elicit-
ed by a 60 Hz alternating current at 50 mA deliv-
ered for 0.2 s via corneal electrodes. A drop of 0.9%
NaCl solution was instilled in each eye prior to
application of the electrodes. The abolition of the
hindlimb tonic extension component of the seizure
was defined as protection in the MES test. The
ScMet test was conducted by administering 85
mg/kg of pentylenetetrazole dissolved in 0.9%
NaCl solution into the posterior midline of mice. A
minimal time of 30 min subsequent to the s.c.
administration of pentylenetetrazole was used for
seizure detection. Neurotoxicity was measured in
mice by the rotorod test. The details of the testing
procedures have been published (8).
Lipophilicity
The log P values of the compounds tested were cal-
culated using two programs with different algo-
rithms: clog P ñ the fragmental approach (9) and
Pallas 3.1.1.2 ñ the combined atomic-fragmental
approach (10).
Table 2. Anticonvulsant and neurotoxicity screening data for unsaturated phthalimides (10-18)
Compd. Dose Activity
no. [mg/kg] MESa ScMetb Toxc
0.5h 4h 0.5 4 0.5 4
30 0/1 0/1 0/1 0/1 0/4 0/2
10 100 2/3 1/3 0/1 0/1 0/8 0/4
300 1/1 1/1 1/1 0/1 4/4 1/2
30 0/1 0/1 0/1 0/1 0/4 0/2
11 100 0/3 0/3 0/1 0/1 0/8 0/4
300 1/1 0/1 0/1 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
12 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
13 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
14 100 0/3 0/3 0/1 0/1 1/8 0/4
300 1/1 0/1 1/1 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
15 100 0/3 0/3 0/1 0/1 1/8 0/4
300 0/1 0/1 0/1 0/1 3/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
16 100 0/3 0/3 0/1 0/1 1/8 1/4
300 0/1 0/1 0/1 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
17 100 0/3 0/3 0/1 0/1 0/8 0/4
300 0/1 0/1 0/1 0/1 2/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
18 100 0/3 0/3 0/1 0/1 2/8 0/4
300 0/1 0/1 0/1 0/1 1/4 0/2
a Number of animals protected/number of animals tested in the MES test.
b Number of animals protected/number of animals tested in the ScMet test.
c Number of animals exhibiting toxicity/number of animals tested in the rotorod test.
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RESULTS AND DISCUSSION
Among the unsaturated derivatives, only com-
pound 12 was devoid of activity in both of the con-
vulsant tests and showed no neurotoxicity at any of
the doses studied. In contrast, all of the phe-
noxyalkyl phthalimides were inactive in the MES
test and the majority of them did not exhibit neuro-
toxicity at doses of up to 300 mg/kg (compounds 2,
3, 4, 6, 7, 8, 9). Only compound 5 showed neuro-
toxicity at doses of 100 and 300 mg/kg at 30 min
after administration. Anti-MES activity of 300
mg/kg at 30 min was recorded for compounds 10, 11
and 14, but all of them exhibited neurotoxicity at the
same or lower dose. Only compound 10 showed
anticonvulsant activity in this test at a dose of 100
mg/kg at 30 min and 4 h and exhibited a lesser
degree of neurotoxicity (300 mg/kg; 30 min, 4 h).
The most neurotoxic of the compounds investigated
were 14, 15, 16 and 18 (100 mg/kg, 300 mg/kg; 30
min). Compound 16 was toxic at a dose of 100
mg/kg at both the investigated time points (30 min,
4 h). In the ScMet test only compounds 1, 10 and 14
were active at the highest dose (300 mg/kg) after 30
min. Only compound 1 was active in this model and
devoid of neurotoxicity. 
The log P values calculated for the compounds
obtained vary from 1.29 to 6.56. It is known that
compounds expected to act in the CNS should pos-
sess log P ~2. The predicted log P value for 10, the
most active compound, is 1.34 (Pallas) and 1.90
(clogP). The log P values for compounds 1, 11 and
14, belonging to ASP group 2, vary from 1.29 to
4.36. Also in the same range are the log P values for
the compounds that are devoid of activity. 
CONCLUSIONS
Two series of phthalimides ñ one possessing an
N-phenoxyalkyl moiety substituted at position 3 or 4 of
the phenyl ring (1-9) and the other, a series of N-
alkenyl or alkinyl phthalimides (10-18) ñ were
obtained and their anticonvulsant activity was exam-
ined.
The anticonvulsant activity of phthalimides
containing an unsaturated substituent at the phthal-
imide nitrogen was superior to that of the N-phe-
noxyalkyl phthalimides. This suggests that the rigid-
Table 4. Predicted log P values for compounds 1-18
Compd. no. logPPallas clogP ASP
1 3.15 4.36 2
2 2.95 3.21 3
3 2.65 3.14 3
4 2.84 3.21 3
5 2.96 3.57 3
6 2.41 2.53 3
7 3.25 3.31 3
8 3.87 4.46 3
9 2.48 2.63 3
10 1.34 1.90 1
11 1.29 2.05 2
12 2.97 2.88 3
13 2.97 2.88 3
14 2.97 2.74 2
15 2.97 2.74 3
16 4.30 3.75 3
17 4.30 3.75 3
18 6.56 5.27 3
The ASP classification is: 1 ñ anticonvulsant activity at doses of 100 mg/kg or less; 2 ñ anticonvulsant activi-
ty at doses greater than 100 mg/kg; 3 ñ compound inactive at 300 mg/kg.
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ity of the molecule influences the activity of this
group of compounds. Alkynyl derivative 10
emerges as the most active (MES and ScMet tests)
of all the compounds tested. The activity of the
unsaturated phthalimides depended on the length
and configuration of the alkenyl chain. Activity was
shown by derivatives possessing a limited chain
length (up to 6 carbon atoms). The results obtained
showed that the cis configuration of the alkenyl
chain was more beneficial to activity than the trans
configuration (14→13). Among the compounds
containing a phenoxyalkyl substituent only the p-
tert-butylphenoxyethyl derivative was active. Here
the length of the alkyl linker was critical for activity
since the propyl derivative (8) showed a lack of
activity in comparison to the ethyl one (1).
Compounds possessing the phenoxyalkyl sub-
stituent showed lower neurotoxicity in comparison
to unsaturated derivatives. A correlation between
anticonvulsant activity and in silico estimated
lipophilicity was not observed. 
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